Nusinersen demonstrates effectiveness in treating spinal muscular atrophy: findings from a three-year nationwide study in Korea

Nusinersen demonstrates effectiveness in treating spinal muscular atrophy: findings from a three-year nationwide study in Korea

IntroductionNusinersen is the first drug approved for spinal muscular atrophy (SMA) treatment. In this study, we aimed to evaluate the long-term safety and efficacy of nusinersen, assess the therapeutic effects based on the treatment initiation timing and baseline motor function, and explore the per...

Full description

Bibliographic Details
Main Authors: Jaeso Cho, Jiwon Lee, Jihye Kim, Hyunjoo Lee, Min-Jee Kim, Yun Jeong Lee, Mi-Sun Yum, Ji-Hye Byun, Chong Guk Lee, Young-Mock Lee, Jeehun Lee, Jong-Hee Chae
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-12-01
Series:Frontiers in Neurology
Subjects:
spinal muscular atrophy
nusinersen
Spinraza
long-term effect
early treatment
Online Access:https://www.frontiersin.org/articles/10.3389/fneur.2023.1294028/full

Internet

https://www.frontiersin.org/articles/10.3389/fneur.2023.1294028/full

Similar Items